Rockville, MD - At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
BLI is a new technology that uses the making and giving off of light by an organism to map diseases in a non-invasive way. Scientists have harnessed this technology to delicately detect and monitor various diseases, including eye cancer. BLI has several advantages over biopsy analysis, including in vivo monitoring, higher sensitivity, easier use and an overall more accurate correlation between cell numbers detected and tumor growth.
A study detailed in the Association for Research in Vision and Ophthalmology's peer-reviewed Investigative Ophthalmology & Visual Science ("Non-invasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging") shows how the researchers, led by Qian Huang, MD, PhD, of the First People's Hospital in Shanghai, China, were able to effectively create human eye tumors in mice using particular genes to label eye cancer.
BLI was then performed on the mice using the NightOwl LB 981 Molecular Imaging System to monitor the growth and succession of these created tumors.
"BLI allowed sensitive and quantitative localization and monitoring of intraocular and metastatic tumor growth in vivo and thus might be a useful tool to study cancer biology as well as anti-cancer therapies," said Huang.
Eye cancer is the most common and aggressive form of cancer found in children under the age of 5. As with most cancers, locating the tumors during the early stages of the disease is key. "Eye removal is usually performed for larger tumors. Small tumors are treated using therapeutic approaches such as chemotherapy. Because of the fast progression, early detection is important for preservation of vision, eye retention and even survival," says Huang.
Investigative Ophthalmology & Visual Science (IOVS) - a peer-reviewed journal published monthly online and in print (through December 2009), IOVS publishes results from original hypothesis-based clinical and laboratory research studies. IOVS ranks No. 4 in Impact Factor among ophthalmology journals.
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. The Association encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology. For more information, visit www.arvo.org.